Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, KURA, SNDX, LYEL, and represent 100.00% of Foresite Capital Management IV's stock portfolio.
  • Added to shares of these 1 stock: PHVS.
  • Reduced shares in these 1 stock: Kinnate Biopharma (-$26M).
  • Sold out of its position in Kinnate Biopharma.
  • Foresite Capital Management IV was a net seller of stock by $-21M.
  • Foresite Capital Management IV has $149M in assets under management (AUM), dropping by -24.79%.
  • Central Index Key (CIK): 0001704132

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Foresite Capital Management IV holds 4 positions in its portfolio as reported in the June 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 54.2 $81M +6% 4.3M 18.80
 View chart
Kura Oncology (KURA) 25.6 $38M 1.8M 20.59
 View chart
Syndax Pharmaceuticals (SNDX) 12.1 $18M 875k 20.53
 View chart
Lyell Immunopharma (LYEL) 8.1 $12M 8.3M 1.45
 View chart

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017

View all past filings